Get the latest news, insights, and market updates on BLTE (Belite Bio, Inc). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Dry Age-related Macular Degeneration Market Poised for Rapid Growth During the Forecast Period (2025–2034) Amid Expanding Treatment Landscape | DelveInsight
The overall dry AMD market size in the US is anticipated to increase, due to the uptake of recently approved therapies, the launch of emerging therapies such as Gildeuretinol (Alkeus Pharmaceuticals), Tinlarebant (Belite Bio), ANX007 (Annexon Biosciences), JNJ-1887 (Johnson & Johnson Innovative Medicine), AVD-104 (Aviceda Therapeutics), OpRegen (Lineage Cell Therapeutics and Roche), OCU410 (Ocugen), Elamipretide (Stealth BioTherapeutics), and others, an increase in diagnosis rate, and others.New Nov 17, 2025 - $BLTE
Belite Bio (BLTE): Exploring Valuation Following Recent Share Price Surge
Belite Bio (BLTE) shares have climbed nearly 44% over the past month, catching the attention of growth-oriented investors. The company’s momentum stands out in a volatile biotech sector and has prompted closer looks at what is driving recent gains. See our latest analysis for Belite Bio. Belite Bio's recent surge is part of a much bigger story, with a 44% jump in the last month helping to fuel an impressive 80% share price return year-to-date. Momentum has really kicked in, and while there... Nov 15, 2025 - $BLTE
Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Completed enrollment with 530 subjects in the pivotal phase 3 PHOENIX trial in geographic atrophy (GA)Completed $15 million registered direct offering and $125 million private placement with potential for up to an additional $165 million upon full warrant exerciseCompleted pivotal phase 3 DRAGON trial in Stargardt disease (STGD); final topline data expected in Q4 2025China’s NMPA has agreed to accept New Drug Application with priority review for Tinlarebant for the treatment of Stargardt disease Nov 10, 2025 - $BLTE
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.comNEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Depositary Receipts Virtual Investor Conference (“dbVIC”) held November 4th are now available for online viewing. VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloa Nov 5, 2025 - $BLTE
Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, November 10, 2025, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the third quarter ended September 30, 2025. Webcast InformationDate: Monday, Nove Nov 3, 2025 - $BLTE
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, November 04, 2025, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the U.S. Representatives from participating companies based in Australia, China, Hong Kong, Germany, Spain, Sweden, and the Cayman Islands will respond to questions during formal presentations. The con Oct 31, 2025 - $BLTE
CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- In a release issued yesterday October 30, 2025 by Virtual Investor Conferences, please note several agenda items were modified. The corrected release follows: Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, November 04, 2025, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the U.S. Representatives from participatin Oct 31, 2025 - $BLTE
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple